George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
This extract taken from rns 29 Sept
"Most notably the Phase I clinical trial evaluating the safety and tolerability of AVA6000 is making excellent progress and is now recruiting patients into the fourth dose escalation cohort, at a dose of 200 mg/m2"
If Avacta were still recruiting on the 29th, presumably we shouldn't expect any news until early/mid December.
Don't disagree. But chasing rainbows? Could be argued I did that when I first invested. However, have always believed in the possibilities, & pretty confident patience could soon be rewarded.
As you know, our sp has been manipulated on numerous occasions, so if the next rns only contains details of a 5th cohort, it wouldn't be a big surprise to see the sp drop below the open offer price, thereby offering a better opportunity to add.
Good luck
Ice. Selling up & being researched nothing to do with my comment. There will be a rns soon the contents of which will determine whether or not 95p is wonderful opportunity or not. Should it only tell us a 5th cohort is planned, I wouldn't be surprised if the sp reaction was to drop below the open offer. Hopefully, we will get an heads up on the data.
Gmcc. Wasn't meant as a correction. I have no idea about the technicalities of the therapeutics, so rely on contributors like yourself to highlight & discuss possibilities & ramifications. I'm invested here because the technology is disruptive, advanced, & endorsed by companies within the biotech arena (witnessed by the jv & licensees).